Phosphatidylinositol 3'-kinase, mTOR, and Glycogen synthase kinase-3 mediated regulation of p21 in human urothelial carcinoma cells

BMC Urology

Volumn 11, Issue , 2011, Pages

  Yohn, Nicole L ^a   Bingaman, Caitlyn N ^a   Dumont, Ashley L ^a   Yoo, Lina I ^a  

^a DENISON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; PROTEIN KINASE INHIBITOR; PROTEIN P21; RAPAMYCIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL STRAIN; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHOSPHORYLATION; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; UROTHELIUM; ANIMAL; BIOSYNTHESIS; BLADDER TUMOR; METABOLISM; PHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 80052026207     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-11-19     Document Type: Article

References (47)

1. PTEN and the PI3-kinase pathway in cancer. Chalhoub N, Baker SJ, Annu Rev Pathol 2009 4 127 150 10.1146/annurev.pathol.4.110807.092311 18767981
2. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Wang DS, Rieger-Christ K, Latini JM, Moinzadeh A, Stoffel J, Pezza JA, Saini K, Libertino JA, Summerhayes IC, Int J Cancer 2000 88 620 625 10.1002/1097- 0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z 11058880
3. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA, Clin Cancer Res 2009 15 6008 6017 10.1158/1078-0432.CCR-09-0898 19789314
4. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y, Hamada K, Yajima N, Kawahara K, Sasaki M, Tsuchiya N, Enomoto K, Mak TW, Nakano T, Habuchi T, Suzuki A, Cancer Res 2006 66 8389 8396 10.1158/0008-5472.CAN-05-4627 16951148 (Pubitemid 44449149)
5. Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Harris LD, De La Cerda J, Tuziak T, Rosen D, Xiao L, Shen Y, Sabichi AL, Czerniak B, Grossman HB, Mol Carcinog 2008 47 678 685 10.1002/mc.20420 18288642
6. Clinical value of PTEN in patients with superficial bladder cancer. Han KS, Jeong IG, Joung JY, Yang SO, Chung J, Seo HK, Kwon KS, Park WS, Lee KH, Urol Int 2008 80 264 269 10.1159/000127338 18480628 (Pubitemid 351693075)
7. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Liedberg F, Anderson H, Chebil G, Gudjonsson S, Hoglund M, Lindgren D, Lundberg LM, Lovgren K, Ferno M, Mansson W, Urol Oncol 2008 26 17 24 10.1016/j.urolonc.2006.08.021 18190825
8. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB, Oncogene 2000 19 5406 5412 10.1038/sj.onc.1203918 11103942
9. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Tanaka M, Grossman HB, Gene Ther 2003 10 1636 1642 10.1038/sj.gt.3302056 12923562 (Pubitemid 37069491)
10. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C, BJU Int 2004 93 143 150 10.1111/j.1464-410X.2004.04574.x 14678387 (Pubitemid 38112985)
11. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, Frierson HF, Theodorescu D, Oncogene 2004 23 6788 6797 10.1038/sj.onc.1207599 15273733 (Pubitemid 39280010)
12. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK, Proc Natl Acad Sci USA 1998 95 13513 13518 10.1073/pnas.95.23.13513 9811831 (Pubitemid 28523003)
13. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. Maehama T, Dixon JE, J Biol Chem 1998 273 13375 13378 10.1074/jbc.273.22.13375 9593664 (Pubitemid 28268370)
14. The phosphoinositide 3-kinase pathway. Cantley LC, Science 2002 296 1655 1657 10.1126/science.296.5573.1655 12040186 (Pubitemid 34579158)
15. PI3K/Akt: getting it right matters. Franke TF, Oncogene 2008 27 6473 6488 10.1038/onc.2008.313 18955974
16. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA, Nature 1995 378 785 789 10.1038/378785a0 8524413 (Pubitemid 26004411)
17. Glycogen synthase kinase 3: more than a namesake. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A, Br J Pharmacol 2009 156 885 898 10.1111/j.1476-5381. 2008.00085.x 19366350
18. Dysregulation of the TSC-mTOR pathway in human disease. Inoki K, Corradetti MN, Guan KL, Nat Genet 2005 37 19 24 10.1038/ng1494 15624019 (Pubitemid 40070934)
19. Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Yoo LI, Liu DW, Le Vu S, Bronson RT, Wu H, Yuan J, Cancer Res 2006 66 1929 1939 10.1158/0008-5472.CAN-05-1986 16488991
20. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC, Nat Cell Biol 2001 3 245 252 10.1038/35060032 11231573 (Pubitemid 32201319)
21. Akt-mediated liver growth promotes induction of cyclin E through a novel translational mechanism and a p21-mediated cell cycle arrest. Mullany LK, Nelsen CJ, Hanse EA, Goggin MM, Anttila CK, Peterson M, Bitterman PB, Raghavan A, Crary GS, Albrecht JH, J Biol Chem 2007 282 21244 21252 10.1074/jbc.M702110200 17517888 (Pubitemid 47099959)
22. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modiano JF, Weiss RH, Mol Cancer 2007 6 16 10.1186/1476-4598-6-16 17300726 (Pubitemid 46351583)
23. P21 and p27: roles in carcinogenesis and drug resistance. Abukhdeir AM, Park BH, Expert Rev Mol Med 2008 10 19 18590585
24. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M, Cancer Res 2001 61 6234 6238 11507077
25. Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Clasen S, Schulz WA, Gerharz CD, Grimm MO, Christoph F, Schmitz-Drager BJ, Br J Cancer 1998 77 515 521 10.1038/bjc.1998.84 9484805 (Pubitemid 28059455)
26. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, Meyer F, Fradet Y, Int J Cancer 2000 89 100 104 10.1002/(SICI)1097- 0215(20000120)89:1<100::AID-IJC16>3.0.CO;2-Q 10719738 (Pubitemid 30078757)
27. The expression of oncoproteins in transitional cell carcinoma: its correlation with pathological behavior, cell cycle and drug resistance. Yu DS, Chang SY, Urol Int 2002 69 46 50 10.1159/000064360 12119439 (Pubitemid 34765294)
28. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer. Korkolopoulou P, Konstantinidou AE, Thomas-Tsagli E, Christodoulou P, Kapralos P, Davaris P, Appl Immunohistochem Mol Morphol 2000 8 285 292 10.1097/00022744-200012000-00005 11127920
29. Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer. Primdahl H, von der Maase H, Sorensen FB, Wolf H, Orntoft TF, J Cancer Res Clin Oncol 2002 128 295 301 10.1007/s00432-002-0344-3 12073046 (Pubitemid 34569349)
30. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, Groshen S, Taylor CR, Jones PA, Skinner DG, Cote RJ, J Natl Cancer Inst 1998 90 1072 1079 10.1093/jnci/90.14.1072 9672255 (Pubitemid 28350272)
31. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H, Genesis 2002 32 148 9 10.1002/gene.10036 11857804 (Pubitemid 34211723)
32. Inducible gene knockouts in the small intestinal and colonic epithelium. Saam JR, Gordon JI, J Biol Chem 1999 274 38071 82 10.1074/jbc.274.53.38071 10608876 (Pubitemid 30026877)
33. Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation. Bjorge JD, Chan TO, Antczak M, Kung HJ, Fujita DJ, Proc Natl Acad Sci USA 1990 87 3816 3820 10.1073/pnas.87.10.3816 2160078 (Pubitemid 20182550)
34. Phosphorylation of the PDGF receptor beta subunit creates a tight binding site for phosphatidylinositol 3 kinase. Kazlauskas A, Cooper JA, EMBO J 1990 9 3279 3286 2170111
35. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. Fuentealba LC, Elvers E, Ikeda A, Hurtado C, Kuroda H, Pera EM, De Robertis EM, Cell 2007 131 980 93 10.1016/j.cell.2007.09.027 18045539 (Pubitemid 350138081)
36. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Cully M, You H, Levine AJ, Mak TW, Nat Rev Cancer 2006 6 184 192 10.1038/nrc1819 16453012 (Pubitemid 43292562)
37. Regulation of cell proliferation by induction of p21/WAF1 in rat bladder carcinoma cells using the Cre - loxP system. AIto A, Asamoto M, Hokaiwado N, Shirai T, Cancer Lett 2003 193 183 188 10.1016/S0304-3835(03)00007-7 12706876 (Pubitemid 36428901)
38. Up-regulation of p21WAF1/Cip1 by saRNA induces G1-phase arrest and apoptosis in T24 human bladder cancer cells. Yang K, Zheng XY, Qin J, Wang YB, Bai Y, Mao QQ, Wan Q, Wu ZM, Xie LP, Cancer Lett 2008 265 206 214 10.1016/j.canlet.2008.02.014 18358601
39. Antitumor effect of dsRNA-induced p21(WAF1/CIP1) gene activation in human bladder cancer cells. Chen Z, Place RF, Jia ZJ, Pookot D, Dahiya R, Li LC, Mol Cancer Ther 2008 7 698 703 10.1158/1535-7163.MCT-07-2312 18347154 (Pubitemid 351482152)
40. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Chion E, Lee IL, Dadbin A, Sabichi AL, Harris L, Urbauer D, McConkey DJ, Dickstein RJ, Cheng T, Grossman HB, Clin Cancer Res 2011 17 2863 73 10.1158/1078-0432.CCR-09-3202 21415218
41. GSK-3: tricks of the trade for a multi-tasking kinase. Doble BW, Woodgett JR, J Cell Sci 2003 116 1175 1186 10.1242/jcs.00384 12615961 (Pubitemid 36410657)
42. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Diehl JA, Cheng M, Roussel MF, Sherr CJ, Genes Dev 1998 12 3499 3511 10.1101/gad.12.22.3499 9832503 (Pubitemid 28553242)
43. Glycogen synthase kinase-3beta and p38 phosphorylate cyclin D2 on Thr280 to trigger its ubiquitin/proteasome-dependent degradation in hematopoietic cells. Kida A, Kakihana K, Kotani S, Kurosu T, Miura O, Oncogene 2007 26 6630 6640 10.1038/sj.onc.1210490 17486076 (Pubitemid 47573686)
44. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S, J Biol Chem 2002 277 9684 9689 10.1074/jbc.M106157200 11779850 (Pubitemid 34968067)
45. N-acetylation and ubiquitin-independent proteasomal degradation of p21(Cip1). Chen X, Chi Y, Bloecher A, Aebersold R, Clurman BE, Roberts JM, Mol Cell 2004 16 839 847 10.1016/j.molcel.2004.11.011 15574338 (Pubitemid 39586541)
46. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. Li Y, Dowbenko D, Lasky LA, J Biol Chem 2002 277 11352 11361 10.1074/jbc.M109062200 11756412 (Pubitemid 34952901)
47. GSK3beta: role in therapeutic landscape and development of modulators. Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN, Br J Pharmacol 2010 160 1 19 10.1111/j.1476-5381.2010.00661.x 20331603